Our most advanced product candidate, roxadustat, is progressing through a global Phase 3 clinical development program for the treatment of anemia in chronic kidney disease, and recently entered Phase 3 development in the U.S. and will soon start Phase 2/3 development in China for treatment of anemia associated with myelodysplastic syndromes. The goal of these clinical studies is to evaluate the safety and efficacy of the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor therapy for the treatment of anemia.

• FG-4592-064, Phase 3, Anemia in dialysis-dependent CKD patients
  >  Active, not recruiting 
• FG-4592-063, Phase 3, Anemia in incident dialysis-dependent CKD patients
  >  Active, not recruiting 
• FG-4592-060, Phase 3, Anemia in non-dialysis-dependent CKD patients
  >  Active, not recruiting
• FG-4592-082, Phase 3, Anemia in MDS patients
  > Currently enrolling